Trial · NCT00467844

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

NCT00467844, Phase 2, Completed, GTx; results first posted 2013-02-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. Trials, record NCT00467844. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00467844

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
NCT number: NCT00467844
Status: Completed
Phases: Phase 2
Enrollment: 159 participants, actual
Lead sponsor: GTx
Conditions: Cachexia
Interventions: GTx-024, GTx-024, Placebo
First posted: 2007-05-01
Last updated: 2014-07-11
Results first posted: 2013-02-21

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Efficacy of GTx-024 on Total Body Lean Mass.	Baseline to Four Months	Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.
Secondary	To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.	Four Months	Change in stair climb power from baseline to 4 months. Stair climb power is defined power (watts)=\[9.8 m/sec\\2\]\\[weight (kg)\]\\[height of 12 steps(meters)\]/ \[time (seconds) up the 12 steps\].

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Efficacy of GTx-024 on Total Body Lean Mass.	Baseline to Four Months	The number of participants were those subjects in the modified intent-to-treat population (defined as subjects with at least one post baseline DEXA for LBM) who had baseline and 4 month DEXA results for LBM (observed cases).	kg	MEDIAN
SECONDARY	To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.	Four Months	The subjects were in the MITT population (had a post baseline DEXA) and had a month 4 stair climb assessment (observed cases).	watts	MEDIAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
The Efficacy of GTx-024 on Total Body Lean Mass.	GTx-024 1 mg	1.55	Full Range -2.06 to 12.64	kg
The Efficacy of GTx-024 on Total Body Lean Mass.	GTx-024 3 mg	0.98	Full Range -4.84 to 11.54	kg
The Efficacy of GTx-024 on Total Body Lean Mass.	Placebo	0.02	Full Range -5.81 to 7.46	kg
To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.	GTx -024	19.93	Full Range -235.3 to 110.1	watts
To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.	GTx-024	12.84	Full Range -77.7 to 93.1	watts
To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.	3 mg of Placebo	11.34	Full Range -156.4 to 56.4	watts

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	GTx -024	53
Overall Study	STARTED	GTx-024	54
Overall Study	STARTED	3 mg of Placebo	52
Overall Study	COMPLETED	GTx -024	34
Overall Study	COMPLETED	GTx-024	34
Overall Study	COMPLETED	3 mg of Placebo	38
Overall Study	NOT COMPLETED	GTx -024	19
Overall Study	NOT COMPLETED	GTx-024	20
Overall Study	NOT COMPLETED	3 mg of Placebo	14

Source ClinicalTrials.gov

Adverse events171

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	anaemia	Blood and lymphatic system disorders	GTx -024	13	53
other	anaemia	Blood and lymphatic system disorders	GTx-024	7	54
other	anaemia	Blood and lymphatic system disorders	3 mg of Placebo	8	52
other	neutropenia	Blood and lymphatic system disorders	GTx -024	3	53
other	neutropenia	Blood and lymphatic system disorders	GTx-024	5	54
other	neutropenia	Blood and lymphatic system disorders	3 mg of Placebo	2	52
other	thrombocytopenia	Blood and lymphatic system disorders	GTx -024	3	53
other	thrombocytopenia	Blood and lymphatic system disorders	GTx-024	5	54
other	thrombocytopenia	Blood and lymphatic system disorders	3 mg of Placebo	3	52
other	abdominal pain	Gastrointestinal disorders	GTx -024	2	53

1 to 10 of 171Source ClinicalTrials.gov

See all 171 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	GTx -024
Total, all-cause mortality	GTx-024
Total, all-cause mortality	3 mg of Placebo
Total, other adverse events	GTx -024	47	53
Total, other adverse events	GTx-024	49	54
Total, other adverse events	3 mg of Placebo	46	52
Total, serious adverse events	GTx -024	14	53
Total, serious adverse events	GTx-024	15	54
Total, serious adverse events	3 mg of Placebo	17	52

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
23499390	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00467844

GET https://conductscience.org/api/trials/v1/NCT00467844/events?page=2

API reference For AI assistants